title: Alteplase beyond three hours in ischemic stroke: do we know enough?
authors.forename: Ali
authors.initials: A
authors.lastname: Jawaid
authors.forename: Olivia
authors.initials: O
authors.lastname: Fitch
authors.forename: Salah
authors.initials: S
authors.lastname: Qureshi
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Wilson
authors.forename: Paul E
authors.initials: PE
authors.lastname: Schulz
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D020127:Recovery of Function; D020521:Stroke / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator